Patients with piperacillin–tazobactam allergy labels tolerate other beta‐lactams
Clinical & Experimental Allergy · 2024-07 · 54 (7) · 521-523
DOI: 10.1111/cea.14490 ↗At a glance
Leserbrief in Clinical & Experimental Allergy, published online on 2024-05-02. Written by Michael Taggart and 2 co-authors. Institution: Allergy, Asthma and Clinical Immunology, The Alfred, Melbourne, Victoria, Australia. Major MEDLINE topics: Drug Hypersensitivity, Piperacillin, Tazobactam Drug Combination, beta-Lactams, Anti-Bacterial Agents. Cited 6 times so far (Crossref); 9 references.
Abstract (original language)
were selectively sensitised to piperacillin-tazobactam. 9 Twelve of these patients were challenged to alternative penicillins and there were no reactions.6 Of the eight immediate-type reactors sensitised to other penicillins, no drug challenges were performed, and therefore, the number with true allergy to alternative penicillins is uncertain.While this 'real-world' cohort outside of highly selected populations attending allergy clinics represents the largest characterised group with piperacillin-tazobactam allergy labels to date, it is possible that treating clinicians only administered alternative beta-lactams to those with lower risk allergy histories.However, the proportion of patients whose index reaction label was consistent with anaphylaxis did not significantly differ between those who were administered another beta-lactam and those who were not.The majority who were not administered another beta-lactam simply had not required any further beta-lactam treatment (22/36, 61.1%).Almost all patients with non-SCAR piperacillin-tazobactam allergy labels were able to tolerate other beta-lactams during routine clinical care without prior skin testing.This was true even for those with a history of an immediatetype index reaction where >98% of alternative beta-lactams were tolerated.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Allergy, Asthma and Clinical Immunology, The Alfred, Melbourne, Victoria, Australia.
ORCID profiles: Michael Taggart, Mark Hew, Celia Zubrinich
Cite
APA
Taggart, M., Hew, M., & Zubrinich, C. (2024). Patients with piperacillin–tazobactam allergy labels tolerate other beta‐lactams. Clinical & Experimental Allergy, 54(7), 521-523. https://doi.org/10.1111/cea.14490
Vancouver
Taggart M, Hew M, Zubrinich C. Patients with piperacillin–tazobactam allergy labels tolerate other beta‐lactams. Clinical & Experimental Allergy. 2024;54(7):521-523. doi:10.1111/cea.14490
BibTeX
@article{Taggart2024,
author = {Taggart, Michael and Hew, Mark and Zubrinich, Celia},
title = {Patients with piperacillin–tazobactam allergy labels tolerate other beta‐lactams},
journal = {Clinical & Experimental Allergy},
year = {2024},
volume = {54},
number = {7},
pages = {521--523},
doi = {10.1111/cea.14490}
}
EUVIMED